ELCC 2018 | A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the use of pembrolizumab monotherapy in the first-line setting, referencing KEYNOTE-024 data (NCT02142738). Prof. Reck then goes on to discuss the next steps for investigating pembrolizumab combination therapy, such as that being explored in the Phase III KEYNOTE-189 trial (NCT02578680). This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Get great new content delivered to your inboxSign up